Adding Ibrance (palbociclib) to standard endocrine therapy failed to prolong the time women with early hormone receptor (HR)-positive, human epidermal growth factor (HER2)-negative breast cancer lived without having their disease return or spread, according to data from a Phase 3 trial. The study, called PENELOPE-B (NCT01864746), was designed to assess if the addition of Ibrance with five years of standard adjuvant endocrine therapy would be superior to a placebo plus standard hormone therapy at prolonging…
You must be logged in to read/download the full post.
The post Adding Ibrance to Hormone Therapy Fails to Prolong Time Before Cancer Recurs, Trial Shows appeared first on BioNewsFeeds.